RT Journal Article
SR Electronic
T1 Serological prevalence of antibodies to SARS CoV-2 amongst cancer centre staff
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.16.20099408
DO 10.1101/2020.05.16.20099408
A1 Karol Sikora
A1 Ian Barwick
A1 Ceri Hamilton
YR 2020
UL http://medrxiv.org/content/early/2020/05/20/2020.05.16.20099408.abstract
AB Objectives the aim of this study was to test Rutherford Health (RH) staff for the presence of SARS CoV-2 antibodies to reduce the risk of infection to cancer patients.Setting Between 14 and 24 April 2020 we tested 161 staff at four locations: our cancer centres in Reading - Berkshire, Newport - S Wales, Liverpool - Merseyside, and Bedlington in Northumberland.Participants Testing was available to all staff who were on site at the four locations named above at the time the study was carried out. 161 staff (80 men, 81 women) gave voluntary consent to have the tests and all testing gave rise to valid results.Interventions We used the South Korean test for antibodies to SARS CoV-2: Sugentech SGTi-flex COVID-19 IgM/IgG1. For each test, blood was collected and added to the sample well of the test cassette and buffer solution added. The test result was legible after 15 minutes. Outcome measures: The number of tests positive for the presence of antibodies was the primary outcome measure. The ratio of tests positive for the presence of IgM antibodies versus IgG antibodies was the secondary outcome measure.Results Between 14 and 24 April 2020, 161 staff (age m = 43) were tested at four Rutherford Cancer Care centres that offer proton beam therapy, radiotherapy and chemotherapy. Out of 161, 12 samples (7.50%) tested positive of which 7 samples (4.35%) detected IgM only, 2 samples (1.24%) detected IgG only and 3 samples (1.86%) detected both IgM and IgG.Conclusions The low seroconversion rate in the sample population limits the current utility of the test as a way of reducing risk to vulnerable patient populations but longitudinal retesting will provide further data.Strengths and limitations of the studyThis is the first UK study on SARS CoV-2 antibody testing using the Sugentech SGTi-flex COVID-19 IgM/IgG in the workplace;This is the first UK study testing a population of cancer centre staff for SARS CoV-2 antibodies;This study builds on similar studies in other countries3-4, albeit with a smaller sample;Data on previous clinical symptoms is not included. We are in the process of revising consent paperwork for the test to include a question about previous symptoms like temperature, dry/persistent cough;Patient data is not included. We will consider testing patients once the pilot test with staff has reached conclusions about the efficacy and value of the test.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study received corporate funding from Rutherford Health PLC for the purchase of the Sugentech SGTi-flex COVID-19 IgM/IgG testing kits and their transport from South Korea. No other additional funding was required to carry out the study.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data can be accessed by emailing peta.evans{at}therutherford.com